Skip to content
BCI.INTEL
NLINKN1 Chip+PRIME.StudySYNCRStentrode+$200M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl
Terminal/Device DB/N1 Implant (Telepathy)
intracorticalIDEinvestigational

N1 Implant (Telepathy)

Implant Type
intracortical
Electrodes
1,024
Channels
1,024
FDA Status
IDE
Clinical Stage
PRIME Feasibility Study
Status
investigational
About

The N1 is Neuralink's first human-implantable BCI, a coin-sized device (23mm x 18mm x 2mm) containing 1,024 electrodes distributed across 64 flexible polymer threads, each thinner than a human hair. The custom ASIC processes 200 Mbps of raw electrode data, compressing it ~200x for Bluetooth Low Energy transmission at ~1 Mbps. The chip is implanted flush with the skull surface by the R1 surgical robot, which precisely inserts the threads into the motor cortex while avoiding surface vasculature. The N1 streams full-band neural signals wirelessly and is inductively recharged through the scalp, achieving approximately 8 hours of operational life per charge. As of September 2025, 12 patients have received implants worldwide. Neuralink plans high-volume production and automated surgery in 2026.

Target Conditions
ALSquadriplegiaspinal cord injury
Milestones
2020-08First public demonstration in pig (Gertrude)
2021-04Monkey (Pager) plays Pong via neural signals
2023-05FDA grants Investigational Device Exemption for human trials
2024-01-28First human implant — Noland Arbaugh, ALS patient
2024-03Noland achieves 8+ hours/day device use; chess and gaming control
2024-08Second human patient (Alex) implanted
2025-01Third human patient implanted; expanded PRIME enrollment
2025-06$650M Series E funding round
2025-0912 patients implanted worldwide; global trial expansion to Canada, UK, Germany, UAE
2025-12Musk announces high-volume production and automated surgery for 2026
FDA Regulatory Pathway
Investigational Device Exemption (IDE)

An IDE permits a device to be used in a clinical study to collect safety and effectiveness data required for a PMA or 510(k) submission. IDE devices are not approved for commercial sale.

FDA Device Regulatory Guidance ↗
Other intracortical Devices